


Esophageal Cancer Market Set for Strong Growth Driven by Rising Incidence & Breakthrough Therapies 2025

The Global Esophageal Cancer Market is expected to reach at a CAGR of 7.8% during the forecast period 2025-2033.

AUSTIN, TX, UNITED STATES,
September 2, 2025 /EINPresswire.com/
-- Market Size and Growth:

DataM Intelligence — The Global [Esophageal Cancer Market](#) continues to grow strongly, valued at USD 1.82 billion in 2024 and projected to nearly double to USD 3.57 billion by 2033, with a CAGR of approximately 7.8%



Spotlight Markets: U.S. & Japan:

“

The Esophageal Cancer Market is expanding with rising incidence, advanced diagnostics, targeted therapies, and growing R&D investments driving global treatment demand.”

DataM Intelligence

United States

- North America held the largest market share 41.16% in 2024 with the U.S. alone accounting for 73.8% of that
- Adoption of precision diagnostics, personalized therapies, and screening campaigns are key demand drivers in the U.S.

Japan

- Japan sits within the Asia-Pacific region, which is the fastest-growing globally, with a CAGR of ~8.7%
- Growth in Japan is propelled by increasing healthcare

access, cancer registries, and technological upgrades in oncology care, supported by public and private sector investments.

To Download Sample Report Here: <https://www.datamintelligence.com/download->

High-Growth Region: Asia-Pacific:

- Asia-Pacific leads in regional growth for the esophageal cancer market, driven by improved urban healthcare infrastructure, increased disposable incomes, and expanding cancer screening outreach
- China alone contributed 12.2% of global revenue in 2024, driven by increased treatment access and investment in oncology centers.

1. Industry Developments (Last 3 Months):

- FDA Approval: In March 2024, the U.S. FDA approved Tevimbra, an anti-PD-1 therapy by BeiGene, for treatment of unresectable or metastatic esophageal squamous cell carcinoma in patients post-chemotherapy.
- This approval is expected to enhance treatment offerings and market expansion for immunotherapies in esophageal cancer.

2. Recent M&A Activity:

- No major M&A news specific to the esophageal cancer market has emerged in the past three months. However, oncology-focused acquisitions and consolidation may be occurring at broader levels within biopharma.

3. Regulatory & Policy Shifts: U.S. & Japan:

- United States: No new policy mandates were introduced recently; however, continued emphasis on precision medicine and early diagnosis supports demand for advanced therapies.
- Japan: Regulatory oversight remains stable with increasing emphasis on early detection programs and reimbursement support for advanced cancer treatments in the public and private sectors.

4. Product Launches & Pipeline Movements:

- Despite limited public announcements in the last quarter, the approval of Tevimbra is a significant milestone, enriching treatment portfolios and providing an important new option for advanced esophageal carcinoma in the U.S.

Buy Now & Unlock 360° Market Intelligence: <https://www.datamintelligence.com/buy-now-page?report=esophageal-cancer-market>

Market Segmentation:

By Cancer Type: Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Others.

By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiotherapy, Endoscopic Therapy, Others.

By Region: North America, Europe, South America, Asia Pacific, Middle East, and Africa.

Leading Companies in the Esophageal Cancer Market:

Major players:

Pfizer

F. Hoffmann-La Roche

Merck & Co.

AbbVie

Bayer,

Novartis

Sanofi

Bristol-Myers Squibb

AstraZeneca

Gilead Sciences

Amgen

Takeda.

These organizations are advancing drug development through immunotherapies, targeted agents, and comprehensive oncology pipelines.

Unlock 360° Market Intelligence with DataM Subscription Services:

<https://www.datamintelligence.com/reports-subscription>

DataM Intelligence Perspective:

“The esophageal cancer market is expanding across developed and developing economies alike. The U.S. remains the dominant market, leveraging advanced diagnostics and expanding immunotherapy options. In Japan, technological and screening investments are driving growth. Meanwhile, Asia-Pacific especially China and India offers rapid growth potential via improving healthcare access and oncology infrastructure,” says the DataM Intelligence research team.

About DataM Intelligence:

DataM Intelligence is a global leader in market research and consulting, offering rigorous

insights in healthcare, oncology, and life science markets. Our evidence-based approach empowers healthcare leaders with strategic clarity and confidence.

Related Reports:

[Nasopharyngeal Cancer Market](#)

[Gynecological Cancers Therapeutics Market](#)

Sai Kiran

DataM Intelligence 4Market Research

+1 877-441-4866

Sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/845249511>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.